Evidence map›Paper›PMID 30896831›Full record

ArticleMolecular medicine reports2019

Autophagy alleviates the decrease in proliferation of amyloid β1‑42‑treated bone marrow mesenchymal stem cells via the AKT/mTOR signaling pathway.

Bo Yang, Zhenyu Cai, Weilin Zhang, Dali Yin, Wei Zhao, Maowei Yang

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Bo YangDepartment of Orthopedics, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Zhenyu CaiDepartment of Orthopedics, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Weilin ZhangDepartment of Orthopedics, The Fourth Hospital of China Medical University, Shenyang, Liaoning 110032, P.R. China.
Dali YinDepartment of Orthopedics, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Wei ZhaoDepartment of Orthopedics, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Maowei YangDepartment of Orthopedics, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
China Medical University · CNFirst Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) and osteoporosis (OP) are 2 common progressive age‑associated diseases, primarily affecting the elderly worldwide. Accumulating evidence has demonstrated that patients with AD are more likely to suffer from bone mass loss and even OP, but whether it is a pathological feature of AD or secondary to motor dysfunction remains poorly understood. The present study aimed to investigate whether amyloid‑β1‑42 (Aβ1‑42), the typical pathological product of AD, exhibited a negative effect on the proliferation of bone marrow mesenchymal stem cells (BMSCs) and the role of autophagy. The proliferation of BMSCs was measured using a Cell Counting Kit‑8 assay, cell cycle analysis and 5‑ethynyl‑2'‑deoxyuridine (EdU) staining. The autophagy‑associated proteins microtubule‑associated proteins 1A/1B light chain 3B and sequestosome 1 (p62) were evaluated by western blot analysis and autophagosomes were detected by transmission electron microscopy and immunofluorescence. The activity of the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway was measured using western blot analysis, and the autophagy inducer rapamycin (RAPA), inhibitor 3‑methyladenine (3‑MA) and the AKT activator SC79 were also used to investigate the role of AKT/mTOR signaling pathway and autophagy in the proliferation of BMSCs. The results suggested that the proliferation of BMSCs treated with Aβ1‑42 was inhibited, with the autophagy level increasing following treatment with Aβ1‑42 in a dose‑dependent manner, while the AKT/mTOR signaling pathway participated in the regulation of the autophagy level. Activation of autophagy using RAPA inhibited the decrease in proliferation of BMSCs, while suppression of autophagy by 3‑MA and activation of the AKT/mTOR signaling pathway increased the decrease in proliferation of BMSCs caused by Aβ1‑42. It was concluded that Aβ1‑42, as an external stimulus, suppressed the proliferation of BMSCs directly and that the AKT/mTOR signaling pathway participated in the regulation of the level of autophagy. Concomitantly, autophagy may serve as a resistance mechanism in inhibiting the decreased proliferation of BMSCs treated with Aβ1‑42.

Indexed as

AdenineAmyloid beta-PeptidesAnimalsAutophagyBone Marrow CellsCell Cycle CheckpointsCell ProliferationMesenchymal Stem CellsMicrotubule-Associated ProteinsPeptide FragmentsProto-Oncogene Proteins c-aktRatsRats, Sprague-DawleySequestosome-1 ProteinSignal TransductionTOR Serine-Threonine Kinases3-methyladenineAdenineAmyloid beta-Peptidesamyloid beta-protein (1-42)Anxa3 protein, ratMicrotubule-Associated ProteinsPeptide FragmentsProto-Oncogene Proteins c-aktSequestosome-1 ProteinSqstm1 protein, ratTOR Serine-Threonine Kinases

Identifiers

PMID30896831
PMCPMC6471277
OpenAlexW2924594844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.